-
Something wrong with this record ?
Pulsed Field Ablation to Treat Atrial Fibrillation: Autonomic Nervous System Effects
DR. Musikantow, P. Neuzil, J. Petru, JS. Koruth, S. Kralovec, MA. Miller, M. Funasako, M. Chovanec, MK. Turagam, W. Whang, L. Sediva, SR. Dukkipati, VY. Reddy
Language English Country United States
Document type Journal Article
- MeSH
- Atrial Fibrillation * MeSH
- Catheter Ablation * adverse effects MeSH
- Humans MeSH
- Vagus Nerve surgery MeSH
- Prospective Studies MeSH
- Retrospective Studies MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: During atrial fibrillation ablations using thermal energy, the treatment effect is attributed to not just pulmonary vein isolation (PVI), but also to modulation of the autonomic nervous system by ablation of cardiac ganglionated plexi (GP). OBJECTIVES: This study sought to assess the impact of pulsed field ablation (PFA) on the GP in patients undergoing PVI. METHODS: In the retrospective phase, heart rate was assessed pre- versus post-PVI using PFA, cryoballoon ablation, or radiofrequency ablation. In the prospective phase, a pentaspline PFA catheter was used in a protocol: 1) pre-PFA, high-frequency stimulation (HFS) identified GP sites by vagal effects; 2) PVI was performed assessing for repetitive vagal effects over each set of PF applications; 3) mapping defined PVI extent to identify those GP in the ablation zone; and 4) repeat HFS at GP sites to assess for persistence of vagal effects. RESULTS: Between baseline and 3 months, heart rates in the retrospective radiofrequency ablation (n = 40), cryoballoon (n = 40), and PFA (n = 40) cohorts increased by 8.9 ± 11.4, 11.1 ± 9.4, and -0.1 ± 9.2 beats/min, respectively (P= 0.01 PFA vs radiofrequency ablation; P= 0.01 PFA vs cryoballoon ablation). In the prospective phase, pre-PFA HFS in 20 additional patients identified 65 GP sites. During PFA, vagal effects were noted in 45% of first PF applications, persisting through all applications in 83%. HFS post-PFA reproduced vagal effects in 29 of 38 sites (76%) in low-voltage tissue. CONCLUSIONS: PFA has minimal effect on GP. Unlike with thermal ablation, the mechanism by which PFA treats atrial fibrillation is mediated solely by durable PVI.
Homolka Hospital Prague Czech Republic
Icahn School of Medicine at Mount Sinai New York New York USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010562
- 003
- CZ-PrNML
- 005
- 20230801132510.0
- 007
- ta
- 008
- 230718s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jacep.2022.10.028 $2 doi
- 035 __
- $a (PubMed)36752473
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Musikantow, Daniel R $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
- 245 10
- $a Pulsed Field Ablation to Treat Atrial Fibrillation: Autonomic Nervous System Effects / $c DR. Musikantow, P. Neuzil, J. Petru, JS. Koruth, S. Kralovec, MA. Miller, M. Funasako, M. Chovanec, MK. Turagam, W. Whang, L. Sediva, SR. Dukkipati, VY. Reddy
- 520 9_
- $a BACKGROUND: During atrial fibrillation ablations using thermal energy, the treatment effect is attributed to not just pulmonary vein isolation (PVI), but also to modulation of the autonomic nervous system by ablation of cardiac ganglionated plexi (GP). OBJECTIVES: This study sought to assess the impact of pulsed field ablation (PFA) on the GP in patients undergoing PVI. METHODS: In the retrospective phase, heart rate was assessed pre- versus post-PVI using PFA, cryoballoon ablation, or radiofrequency ablation. In the prospective phase, a pentaspline PFA catheter was used in a protocol: 1) pre-PFA, high-frequency stimulation (HFS) identified GP sites by vagal effects; 2) PVI was performed assessing for repetitive vagal effects over each set of PF applications; 3) mapping defined PVI extent to identify those GP in the ablation zone; and 4) repeat HFS at GP sites to assess for persistence of vagal effects. RESULTS: Between baseline and 3 months, heart rates in the retrospective radiofrequency ablation (n = 40), cryoballoon (n = 40), and PFA (n = 40) cohorts increased by 8.9 ± 11.4, 11.1 ± 9.4, and -0.1 ± 9.2 beats/min, respectively (P= 0.01 PFA vs radiofrequency ablation; P= 0.01 PFA vs cryoballoon ablation). In the prospective phase, pre-PFA HFS in 20 additional patients identified 65 GP sites. During PFA, vagal effects were noted in 45% of first PF applications, persisting through all applications in 83%. HFS post-PFA reproduced vagal effects in 29 of 38 sites (76%) in low-voltage tissue. CONCLUSIONS: PFA has minimal effect on GP. Unlike with thermal ablation, the mechanism by which PFA treats atrial fibrillation is mediated solely by durable PVI.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a fibrilace síní $7 D001281
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a prospektivní studie $7 D011446
- 650 12
- $a katetrizační ablace $x škodlivé účinky $7 D017115
- 650 _2
- $a nervus vagus $x chirurgie $7 D014630
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Neuzil, Petr $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Petru, Jan $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Koruth, Jacob S $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
- 700 1_
- $a Kralovec, Stepan $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Miller, Marc A $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
- 700 1_
- $a Funasako, Mortioshi $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Chovanec, Milan $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Turagam, Mohit K $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
- 700 1_
- $a Whang, William $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
- 700 1_
- $a Sediva, Lucie $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Dukkipati, Srinivias R $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
- 700 1_
- $a Reddy, Vivek Y $u Icahn School of Medicine at Mount Sinai, New York, New York, USA; Homolka Hospital, Prague, Czech Republic. Electronic address: vivek.reddy@mountsinai.org
- 773 0_
- $w MED00193518 $t JACC. Clinical electrophysiology $x 2405-5018 $g Roč. 9, č. 4 (2023), s. 481-493
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36752473 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132507 $b ABA008
- 999 __
- $a ok $b bmc $g 1963155 $s 1196827
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 9 $c 4 $d 481-493 $e 20221130 $i 2405-5018 $m JACC. Clinical electrophysiology $n JACC Clin Electrophysiol $x MED00193518
- LZP __
- $a Pubmed-20230718